BDMD vs PLUR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 3/9, indicating poor financial health. Despite a seemingly reasonable Price/Book of 0.77 and a strong Gross Margin of 86.94%, the company is deeply unprofitable with negative operating and net margins, collapsing revenue, and no analyst coverage. The complete absence of Altman Z-Score and intrinsic value calculations, combined with a 5-year return of -89.3%, signals severe distress. Technical indicators and insider sentiment are also weak, reinforcing a high-risk outlook.
PLUR exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.40, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a current ratio of 0.43, suggesting it cannot meet its short-term obligations. While recent quarterly earnings have beaten estimates, the operating margin of -3285.86% and a bearish technical trend (0/100) underscore a high risk of insolvency or significant shareholder dilution. The valuation is disconnected from fundamentals, trading at a high Price/Sales multiple of 26.35 despite sluggish revenue growth.
Compare Another Pair
Related Comparisons
BDMD vs PLUR: Head-to-Head Comparison
This page compares Baird Medical Investment Holdings Limited (BDMD) and Pluri Inc. (PLUR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.